<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02349386</url>
  </required_header>
  <id_info>
    <org_study_id>BHR-200-201</org_study_id>
    <nct_id>NCT02349386</nct_id>
  </id_info>
  <brief_title>Maintaining Suppression of Testosterone With Transdermal Estradiol Gel</brief_title>
  <acronym>MASTERS</acronym>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study of BHR-200 (0.36% Transdermal Estradiol Gel) for the Maintenance of Testosterone Suppression in Men With Advanced Androgen-Sensitive Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BHR Pharma, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>H2O Clinical LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Q2 Solutions</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>BHR Pharma, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this clinical study is to evaluate the safety and efficacy of three
      different doses of BHR-200 (0.36% transdermal estradiol gel) compared to placebo for the
      maintenance of testosterone (T) suppression in men with advanced androgen-sensitive prostate
      cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multi-center, randomized, double-blind, placebo-controlled, dose finding study in
      men with advanced androgen-sensitive prostate cancer. Patients who give informed consent will
      have screening evaluations, and if fulfilling the entry criteria, will be randomized to one
      of 4 treatment groups: 1mL, 2mL or 3mL of 0.36% BHR-200 (transdermal estradiol gel) or
      Placebo. Study drug will be initiated on the day they were scheduled to receive next depot
      GnRH agonist injection. Patients will be offered low-dose radiation to aid in the prevention
      of gynecomastia. Patients will apply the study drug once per day. The first dose of study gel
      will be applied under the supervision of the PI/designee. Subsequent doses will be
      self-administered daily by the patient until he is no longer chemically castrated
      (testosterone levels increase above 50 ng/dL), a rise over baseline PSA of &gt; 0.5 ng/mL is
      observed, or he has completed 52 weeks of study drug administration. At the conclusion of
      study participation, patients will be advised to resume standard of care treatment under the
      supervision of their healthcare provider. While on treatment, patients will be evaluated at
      Day 1 and every 2 weeks, for the first 24 weeks and every 4 weeks thereafter with a final
      post-treatment follow-up visit 2 weeks (+/- 1 week) post last dose administration.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Inability to recruit patients
  </why_stopped>
  <start_date type="Actual">July 2015</start_date>
  <completion_date type="Actual">January 10, 2018</completion_date>
  <primary_completion_date type="Actual">June 14, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>testosterone suppression, defined as the absence of any T level measurement over 50 ng/dL during Weeks 4 to 12.</measure>
    <time_frame>Week 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>testosterone suppression, defined as the absence of any T level over 50 ng/dL during Weeks 4-24.</measure>
    <time_frame>Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of adverse events with special attention given to thromboembolic events.</measure>
    <time_frame>Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum concentrations of: follicle-stimulating hormone (FSH), luteinizing hormone (LH), sex hormone binding globulin (SHBG), and prostate-specific antigen (PSA).</measure>
    <time_frame>Week 24</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Cancer of the Prostate</condition>
  <arm_group>
    <arm_group_label>BHR-200 Low Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 mg estradiol per 1 mL 0.36% BHR-200 (transdermal 17β-estradiol gel) applied daily to the skin for up to 52 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BHR-200 Mid Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 mg estradiol per 2 mL 0.36% BHR-200 (transdermal 17β-estradiol gel) applied daily to the skin for up to 52 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BHR-200 High Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>9 mg estradiol per 3 mL 0.36% BHR-200 (transdermal 17β-estradiol gel) applied daily to the skin for up to 52 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1, 2 or 3 mL of Placebo gel containing 0 mg estradiol applied daily for up to 52 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BHR-200 (0.36% transdermal 17β-estradiol gel)</intervention_name>
    <description>An absorptive hydroalcoholic gel preparation containing 17β-estradiol.</description>
    <arm_group_label>BHR-200 Low Dose</arm_group_label>
    <arm_group_label>BHR-200 Mid Dose</arm_group_label>
    <arm_group_label>BHR-200 High Dose</arm_group_label>
    <other_name>BHR-200</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>An absorptive hydroalcoholic gel preparation gel of the same ingredients as BHR-200, but without 17β-estradiol.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Males, Ages 18 and older

          2. Body Mass Index (BMI) between 18 and 35 kg/m2 (inclusive)

          3. Not currently hospitalized

          4. Clinical indication of adenocarcinoma of the prostate evidenced by a biopsy report on
             record

          5. At present receiving ADT treatment with a GnRH agonist for at least 2 months but not
             longer than 36 months without interruption - Note: If the patient received GnRH
             agonist treatment prior to the treatment described under 5, there must be evidence of
             a period without GnRH agonist treatment for a minimum of 2 months prior to starting
             the present treatment as is seen, for example with intermittent treatment regimens.

          6. Able to initiate Screening procedures 2 weeks prior to the next scheduled injection
             with a GnRH agonist

          7. Willing to discontinue current ADT regimen for the duration of the study

          8. T level less than 50 ng/dL at Screening

          9. WHO/ECOG performance status of 0 or 1

         10. Life expectancy of at least 1 year

         11. Adequate renal function demonstrated by having normal blood urea nitrogen (BUN) and
             Creatinine Screening lab values

        Exclusion Criteria:

          1. History or presence of allergic or adverse response to estradiol

          2. Presence of symptomatic metastatic disease, risk of spinal cord compression or urinary
             obstruction

          3. History within the past 2 years of deep vein thrombosis (DVT), pulmonary embolism
             (PE2), a known thrombophilic disorder (eg.protein C, protein S, or antithrombin
             deficiency), or cerebrovascular accident (CVA)

          4. History within the past 2 years of myocardial infarction or a coronary vascular
             procedure (e.g. percutaneous coronary intervention, coronary artery bypass graft)

          5. History of congestive heart failure

          6. Use of any investigational drug, biologic, or device within 28 days prior to the first
             dose of study gel

          7. Use of any of the following known inducers or inhibitors of cytochrome P450 3A4
             (CYP3A4): phenobarbital, carbamazepine, rifampin, erythromycin, clarithromycin,
             ketoconazole, itraconazole, ritonavir, St. John's Wort preparations (Hypericum
             perforatum), and grapefruit juice

          8. Hematological parameters (Hematocrit or Hemoglobin) outside 20% of the upper or lower
             limits of normal at Screening

          9. Active skin rash, sunburn, or other skin disorder on the upper arm(s) that requires
             treatment or may affect skin absorption of study gel

         10. Resting uncontrolled hypertension (HTN) (160/100 mmHg) at Screening

         11. Co-existent malignancy or a history of malignancy during the past 5 years, with the
             exception of basal and/or squamous cell carcinoma of the skin

         12. Any other significant concurrent illness or disease or condition that in the opinion
             of the Investigator might interfere with the patient's ability to receive the
             treatment outlined in the protocol or might put him at additional risk
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roland Gerritsen van der Hoop, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>BHR Pharma, LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Urological Associates of Southern Arizona</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85741</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Florida Medical Research</name>
      <address>
        <city>Aventura</city>
        <state>Florida</state>
        <zip>33180</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Urology Institute</name>
      <address>
        <city>Daytona Beach</city>
        <state>Florida</state>
        <zip>32114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Adult Pediatric Urology, PC</name>
      <address>
        <city>Council Bluffs</city>
        <state>Iowa</state>
        <zip>51501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Adult Pediatric Urology, PC</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Delaware Valley Urology</name>
      <address>
        <city>Voorhees</city>
        <state>New Jersey</state>
        <zip>08043</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AccumetRX Clinical Trials</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Associated Medical Professionals of NY (AMP of NY)</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eastern Urological Associates</name>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <zip>27834</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urologic Consultants of Southeastern Pennsylvania (UCSEPA)</name>
      <address>
        <city>Bala-Cynwyd</city>
        <state>Pennsylvania</state>
        <zip>19044</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolina Urologic Research Center</name>
      <address>
        <city>Myrtle Beach</city>
        <state>South Carolina</state>
        <zip>29572</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urology Clinics of North Texas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Ockrim JL, Lalani EN, Laniado ME, Carter SS, Abel PD. Transdermal estradiol therapy for advanced prostate cancer--forward to the past? J Urol. 2003 May;169(5):1735-7.</citation>
    <PMID>12686820</PMID>
  </reference>
  <reference>
    <citation>Ockrim JL, Lalani el-N, Kakkar AK, Abel PD. Transdermal estradiol therapy for prostate cancer reduces thrombophilic activation and protects against thromboembolism. J Urol. 2005 Aug;174(2):527-33; discussion 532-3.</citation>
    <PMID>16006886</PMID>
  </reference>
  <reference>
    <citation>Ockrim JL, Abel PD. Long term androgen deprivation therapy in prostate cancer. BMJ. 2008 Sep 22;337:a1361. doi: 10.1136/bmj.a1361.</citation>
    <PMID>18809586</PMID>
  </reference>
  <reference>
    <citation>Ockrim J, Lalani el-N, Abel P. Therapy Insight: parenteral estrogen treatment for prostate cancer--a new dawn for an old therapy. Nat Clin Pract Oncol. 2006 Oct;3(10):552-63. Review.</citation>
    <PMID>17019433</PMID>
  </reference>
  <reference>
    <citation>Langley RE, Godsland IF, Kynaston H, Clarke NW, Rosen SD, Morgan RC, Pollock P, Kockelbergh R, Lalani el-N, Dearnaley D, Parmar M, Abel PD. Early hormonal data from a multicentre phase II trial using transdermal oestrogen patches as first-line hormonal therapy in patients with locally advanced or metastatic prostate cancer. BJU Int. 2008 Aug;102(4):442-5. doi: 10.1111/j.1464-410X.2008.07583.x. Epub 2008 Apr 16.</citation>
    <PMID>18422771</PMID>
  </reference>
  <reference>
    <citation>Langley RE, Cafferty FH, Alhasso AA, Rosen SD, Sundaram SK, Freeman SC, Pollock P, Jinks RC, Godsland IF, Kockelbergh R, Clarke NW, Kynaston HG, Parmar MK, Abel PD. Cardiovascular outcomes in patients with locally advanced and metastatic prostate cancer treated with luteinising-hormone-releasing-hormone agonists or transdermal oestrogen: the randomised, phase 2 MRC PATCH trial (PR09). Lancet Oncol. 2013 Apr;14(4):306-16. doi: 10.1016/S1470-2045(13)70025-1. Epub 2013 Mar 4.</citation>
    <PMID>23465742</PMID>
  </reference>
  <reference>
    <citation>Bland LB, Garzotto M, DeLoughery TG, Ryan CW, Schuff KG, Wersinger EM, Lemmon D, Beer TM. Phase II study of transdermal estradiol in androgen-independent prostate carcinoma. Cancer. 2005 Feb 15;103(4):717-23.</citation>
    <PMID>15641029</PMID>
  </reference>
  <reference>
    <citation>Cox RL, Crawford ED. Estrogens in the treatment of prostate cancer. J Urol. 1995 Dec;154(6):1991-8. Review.</citation>
    <PMID>7500443</PMID>
  </reference>
  <reference>
    <citation>Lycette JL, Bland LB, Garzotto M, Beer TM. Parenteral estrogens for prostate cancer: can a new route of administration overcome old toxicities? Clin Genitourin Cancer. 2006 Dec;5(3):198-205. Review.</citation>
    <PMID>17239273</PMID>
  </reference>
  <reference>
    <citation>Sayed Y, Taxel P. The use of estrogen therapy in men. Curr Opin Pharmacol. 2003 Dec;3(6):650-4. Review.</citation>
    <PMID>14644018</PMID>
  </reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 23, 2015</study_first_submitted>
  <study_first_submitted_qc>January 27, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 28, 2015</study_first_posted>
  <last_update_submitted>April 3, 2018</last_update_submitted>
  <last_update_submitted_qc>April 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Testosterone</mesh_term>
    <mesh_term>Testosterone enanthate</mesh_term>
    <mesh_term>Testosterone undecanoate</mesh_term>
    <mesh_term>Testosterone 17 beta-cypionate</mesh_term>
    <mesh_term>Methyltestosterone</mesh_term>
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Polyestradiol phosphate</mesh_term>
    <mesh_term>Estradiol 3-benzoate</mesh_term>
    <mesh_term>Estradiol 17 beta-cypionate</mesh_term>
    <mesh_term>Estradiol valerate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

